Table 2. Randomized open-label treatment period for 12 weeks .
| Characteristics | Rosuvastatin 10 mg (Group A) (N = 62) | SFC Fenofibrate 80 mg + Rosuvastatin 5 mg (Group B) (N = 50) | p value |
| Waist circumference, cm | 92.14 (10.15) | 94.57 (7.39) | 0.25 |
| Height, cm | 161.73 (9.77) | 162.06 (8.77) | 0.88 |
| Weight, Kg | 72.24 (12.80) | 71.13 (11.65) | 0.69 |
| Cholesterol, mg/dl | |||
| Total | 174.68 (32.76) | 180.46 (29.55) | 0.40 |
| High-density lipoprotein | 45.14 (8.67) | 44.62 (11.15) | 0.80 |
| Low-density lipoprotein | 97.00 (31.85) | 104.63 (25.35) | 0.23 |
| Non high-density lipoprotein | 128.44 (29.58) | 134.76 (27.34) | 0.38 |
| Triglyceride, mg/dl | 162.77 (67.78) | 158.23 (62.05) | 0.75 |
| BUN, mg/dl | 15.19 (4.87) | 19.95 (9.58) | 0.10 |
| Creatinine, mg/dl | 1.08 (0.27) | 1.34 (0.54) | 0.01* |
| eGFR, ml/min/m2 | 70.96 (14.02) | 58.34 (17.77) | 0.001* |
| Fasting plasma glucose, mg/dl | 112.54 (24.58) | 117.27 (32.84) | 0.50 |
| HbA1c, % | 6.42 (1.23) | 8.52 (1.55) | 0.27 |
| Liver enzyme, IU/L | |||
| AST | 29.67 (11.29) | 33.73 (20.10) | 0.29 |
| ALT | 38.12 (21.86) | 34.73 (25.20) | 0.52 |
| Creatinine phosphokinase, IU/L | 111.26 (63.67) | 110.78 (52.60) | 0.97 |
| Uric acid, mg/dl | 6.61 (1.71) | 6.06 (1.33) | 0.30 |
Values are presented as mean (SD) unless stated otherwise.
ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; eGFR, estimated glomerular filtration rate.
* p < 0.05.